Skip to content

Determinants of Repeated Spontaneous Miscarriages and Unexplained Fetal Deaths

Determinants of Repeated Spontaneous Miscarriages and Unexplained Fetal Deaths (DEFI-2)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04207814
Acronym
DEFI-2
Enrollment
200
Registered
2019-12-23
Start date
2020-10-05
Completion date
2057-10-05
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Deaths in Utero, Repeated Spontaneous Miscarriages

Brief summary

The DEFI-1 study recruited 625 women witnesses and 299 of their spouses. With regard to case couples, 271 cases were recruited from the spontaneous repeated miscarriages (SRM) subgroup (≥3 spontaneous miscarriage (SM) from trimester 1 of pregnancy) and 93 from the unexplained fetal death in utero (FDIU) subgroup from trimesters 2 and 3 of pregnancy. The main objective of the DEFI 2 study is to increase the number of case-pairs in these 2 particular subgroups to replicate the results of the genetic determinants highlighted from cases and controls with extreme phenotypes and obtain a sufficient number of women with FDIUs to identify specific determinants.

Detailed description

The spontaneous repeated miscarriages (SRM) affect one to two fertile couples on 100, a fetal death in utero (FDIU) complicates the evolution of a pregnancy on 200. The SRM remain unexplained in 50% of the cases although a beam indirect arguments sometimes encourage to evoke a prothrombotic process and / or endothelial dysfunction, immunological disorders, an alteration of the ovarian reserve, and possibly the impact of genetic determinants. Regarding SRM, in the absence of a fetal, funicular cause or obvious preeclampsia, very diverse mechanisms are evoked depending on the placental histology (vasculoplacental, inflammatory, intervillitis, immunological, etc.). Thus, while these mechanisms remain for some to be demonstrated and are probably not unequivocal, clinicians are faced with a pressing request for therapeutic intervention on the part of patients. This is why, after having studied in DEFI-1 the 2 main constitutional thrombophilia in the 2 members of the couple, the procoagulant circulating microparticles and the generation of thrombin in the mother on the one hand, the modalities of inactivation of an X in the mother, on the other hand, a further investigation in subgroups of particular cases would be appropriate.

Interventions

biological samples will be taken from the subjects included

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Case couples

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* couples whose wife is over 18 and under 40 inclusive, * couples having undergone at least 3 unexplained SM in the first trimester or an FDIU in the trimesters 2 and 3 of pregnancy (excluding funicular and fetal causes and proven preeclampsia) * the man must be over 18 years old. * each member of the couple must consent to the investigation. * Subjects benefiting from a social security scheme.

Exclusion criteria

* couples where the woman is under 18 or over 40, * couples whose man is under 18, * identified cause of SRM or FDIU * Inability to consent for one of the members of the couple, * refusal to participate for one of the members of the couple. * treatment with anticoagulants or anti-aggregating platelet for women. * Person under legal protection * Subjects not benefiting from a social security scheme * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Frequency difference of the determinant between the cases and the controls34 yearsThe frequency difference of the determinant under study between the cases (studies DEFI-1 and DEFI-2) and the controls (study DEFI-1) will be measured.

Secondary

MeasureTime frameDescription
Occurrence of a new medical event34 yearsOccurrence of a new medical event in prospective follow-up will be evaluated

Countries

France

Contacts

CONTACTElisabeth Pasquier, MD
elisabeth.pasquier@chu-brest.fr0298145013
STUDY_DIRECTORElisabeth Pasquier, MD

Brest University Hospital in France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026